These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24203760)

  • 1. Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.
    Arias F; Asín G; Uzcanga MI; Maraví E; Quílez I; Chicata V; Eito C; Viudez A; Hernández I; Mañeru F; Domínguez MA
    Clin Transl Oncol; 2014 Jun; 16(6):555-60. PubMed ID: 24203760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
    Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
    Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer single-institution outcome analysis.
    Pala M; Odrazka K; Holeckova P; Vitek P; Kubes J; Podlesak T; Klozar J; Petruzelka L
    Neoplasma; 2012; 59(2):129-36. PubMed ID: 22248269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
    Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
    Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients.
    Koness RJ; Glicksman A; Liu L; Coachman N; Landman C; Slotman G; Wanebo HJ
    Am J Surg; 1997 Nov; 174(5):532-5. PubMed ID: 9374231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
    Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
    Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
    Adelstein DJ; Moon J; Hanna E; Giri PG; Mills GM; Wolf GT; Urba SG
    Head Neck; 2010 Feb; 32(2):221-8. PubMed ID: 19557750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study.
    Regine WF; Valentino J; John W; Storey G; Sloan D; Kenady D; Patel P; Pulmano C; Arnold SM; Mohiuddin M
    Head Neck; 2000 Sep; 22(6):543-9. PubMed ID: 10941154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
    Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
    Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly Cisplatin-Based Concurrent Chemoradiotherapy for Treatment of Locally Advanced Head and Neck Cancer: a Single Institution Study.
    Ghosh S; Rao PB; Kumar PR; Manam S
    Asian Pac J Cancer Prev; 2015; 16(16):7309-13. PubMed ID: 26514529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
    Gupta P; Dhull AK; Kaushal V
    J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
    Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
    Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
    Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
    Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
    Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
    Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.